AbCellera Biologics Inc. (ABCL) Total Return Calculator with Dividends Reinvested

AbCellera Biologics Inc.

Popular:

The total return for AbCellera Biologics Inc. (ABCL) stock is +59.37% over the past 12 months. So far it's up 61.22% this year. The 5-year total return is -76.15%, meaning $10,000 invested in ABCL stock 5 years ago would be worth $2,385 today. Total return includes price appreciation plus reinvesting any dividends paid out.

If you invested $10,000 in ABCL 1 year ago, it would be worth $16,607 today — you'd have gained $6,607.

With Dividends Reinvested$16,607+66.07%

Price Only (No DRIP)$16,607+66.07%

Period2025-06-23 → 2026-06-18

Price

Total Return (DRIP)

S&P 500

If You Invested $10,000 in ABCL

1Y$15,937+$5,937 (+59.4%)59.4% CAGR

3Y$7,364-$2,636 (-26.4%)-9.7% CAGR

5Y$2,385-$7,615 (-76.2%)-24.9% CAGR

10Y$939-$9,061 (-90.6%)-21.1% CAGR

15Y$939-$9,061 (-90.6%)-14.6% CAGR

20Y$939-$9,061 (-90.6%)-11.2% CAGR

30Y$939-$9,061 (-90.6%)-7.6% CAGR

AbCellera Biologics Inc. did not pay dividends during this period. Total return = price return.

Loading ABCL total return...

As of 2026-06-22

Returns at a Glance

Period	Total Return	CAGR	Price Only	Div. Contrib.	$10K →
YTD	+61.22%	—	+61.22%	—	$16,122
1Y	+59.37%	59.37%	+59.37%	—	$15,937
3Y	-26.36%	-9.70%	-26.36%	—	$7,364
5Y	-76.15%	-24.93%	-76.15%	—	$2,385
10Y	-90.61%	-21.07%	-90.61%	—	$939
15Y	-90.61%	-14.59%	-90.61%	—	$939
20Y	-90.61%	-11.16%	-90.61%	—	$939
30Y	-90.61%	-7.58%	-90.61%	—	$939

Risk & Highlights

Best Year+12.87%2025

Worst Year-63.43%2021

Max Drawdown-54.94%2025-10-08 → 2026-02-05 · Recovered 2026-05-29

Annual Returns

Year	Total Return	Price Return	Div.	S&P 500	vs S&P
2026YTD	+5.25%	+5.25%	—	+0.41%	+4.8pp
2025	+12.87%	+12.87%	—	+16.64%	-3.8pp
2024	-48.87%	-48.87%	—	+24.00%	-72.9pp
2023	-39.83%	-39.83%	—	+24.81%	-64.6pp
2022	-28.36%	-28.36%	—	-19.95%	-8.4pp

ABCL outperformed the S&P 500 by 34.38pp over the past year (+59.37% vs +24.99%).

Loading summary...

ABCL Peers' Total Return

Accurate peer set · 10 comparable names

Name	Mkt Cap	30D Rtn	YTD Total Rtn	1Y Total Rtn	Div Contrib	3Y Total Rtn	5Y Total Rtn	10Y Total Rtn
ABCLAbCellera Biologics Inc.	$1.7B	+32.9%	+61.2%	+59.4%	—	-26.4%	-76.2%	-90.6%
TWSTTwist Bioscience Corporation	$5.5B	+75.9%	+170.3%	+144.0%	—	+380.0%	-21.3%	+525.4%
RXRXRecursion Pharmaceuticals, Inc.	$1.4B	+11.8%	-23.1%	-36.8%	—	-64.0%	-91.1%	-82.1%
SDGRSchrödinger, Inc.	$1.2B	+30.8%	-12.3%	-25.1%	—	-67.2%	-78.7%	-45.0%
BEAMBeam Therapeutics Inc.	$3.5B	+27.3%	+25.8%	+100.9%	—	+2.4%	-59.8%	+82.1%
SEERSeer, Inc.	$96M	+3.0%	-4.4%	-12.1%	—	-62.3%	-94.8%	-96.9%
REGNRegeneron Pharmaceuticals, Inc.	$63.4B	-3.1%	-21.2%	+19.5%	+0.7pp	-21.2%	+14.4%	+74.5%
HALOHalozyme Therapeutics, Inc.	$8.1B	+1.6%	-2.5%	+29.0%	—	+98.3%	+65.5%	+688.4%
XNCRXencor, Inc.	$927M	+14.3%	-15.3%	+51.2%	—	-51.7%	-65.8%	-11.4%
ALNYAlnylam Pharmaceuticals, Inc.	$37.1B	-2.9%	-30.5%	-11.0%	—	+37.9%	+57.2%	+391.0%
IMVTImmunovant, Inc.	$7.3B	+33.2%	+36.4%	+122.8%	—	+77.8%	+214.7%	+255.2%

Compare:ABCL vs TWST ABCL vs RXRX ABCL vs SDGR ABCL vs TWST vs RXRX

About ABCL Dividend Returns

AbCellera Biologics Inc. (ABCL) does not currently pay dividends. Many growth-focused companies reinvest profits back into the business rather than distributing them as dividends.

How We Calculate Total Return

Our total return calculator simulates dividend reinvestment (DRIP) by assuming each dividend payment is used to purchase additional shares at the closing price on the ex-dividend date. This methodology provides an accurate representation of how a dividend reinvestment plan would perform.

Frequently Asked Questions

Q1What is the total return of ABCL over the past year?

AbCellera Biologics Inc. (ABCL) delivered a return of 59.37% over the past year. Since ABCL does not currently pay dividends, the total return equals the price-only return.

Q2How much would $10,000 invested in ABCL be worth today?

A $10,000 investment in AbCellera Biologics Inc. one year ago would be worth $15,937 today, representing a gain of $5,937.

Q3Does ABCL pay dividends?

AbCellera Biologics Inc. (ABCL) does not currently pay dividends. Many growth-focused companies reinvest profits back into the business rather than distributing them as dividends. For ABCL, the total return equals the price-only return.

Q4Did ABCL beat the S&P 500?

Yes, AbCellera Biologics Inc. (ABCL) outperformed the S&P 500 by 34.38 percentage points over the past year. ABCL delivered a total return of 59.37%, compared to the S&P 500's 24.99%. This 34.38pp alpha means investors in ABCL earned more than a passive S&P 500 index fund.

Q5What is ABCL's worst drawdown?

AbCellera Biologics Inc. (ABCL) experienced a maximum drawdown of -54.94% over the past year, declining from its peak on 2025-10-08 to its trough on 2026-02-05. The stock recovered to its prior peak by 2026-05-29. Maximum drawdown measures the worst peak-to-trough decline and is an important risk metric for investors.

Q6What is ABCL's long-term total return over 10, 20, or 30 years?

Here are AbCellera Biologics Inc. (ABCL)'s long-term returns with dividends reinvested. Over 10 years, the total return is -90.6% (-21.1% CAGR) — $10,000 would have grown to $939. Over 20 years: -90.6% total return (-11.2% CAGR) — $10,000 → $939. Over 30 years: -90.6% total return (-7.6% CAGR) — $10,000 → $939. Long-term investors benefit from compounding: dividends buy additional shares, which generate their own dividends, creating an exponential growth effect.

Q7What was ABCL's best and worst year?

AbCellera Biologics Inc.'s best calendar year was 2025 with a total return of 12.9%. Its worst year was 2021 with a total return of -63.4%. This range shows the volatility investors should expect — the difference between the best and worst year is 76.3 percentage points.

How much would $100/month in ABCL be worth today?

Dollar cost averaging calculator · DCA vs lump sum · see how regular investing compounds

Run the Numbers →